Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03648931
Other study ID # MTN-041
Secondary ID UM1AI068633UM1AI
Status Completed
Phase
First received
Last updated
Start date May 31, 2018
Est. completion date November 2, 2018

Study information

Verified date June 2021
Source Microbicide Trials Network
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The MTN-041 study is a multi-site exploratory study using focus group discussions (FGDs) and in-depth interviews (IDIs) to identify individual, interpersonal, social and cultural factors that may affect potential uptake of two safe and effective HIV prevention products, the monthly dapivirine (DPV) vaginal ring (VR) and daily oral pre-exposure prophylaxis (PrEP), by pregnant and breastfeeding women in Africa.


Description:

MTN-041 is an exploratory study primarily designed to identify individual, interpersonal, social and cultural factors that may affect potential uptake of two safe and effective HIV prevention products, the monthly DPV VR and daily oral PrEP, in a vulnerable yet seldom-studied population, pregnant and breastfeeding women. MTN-041 will utilize FGDs and IDIs to elicit community and health professional perceptions about vaginal practices, sexual activity, use of medicines, and HIV risk during pregnancy or breastfeeding, including how these perceptions may affect pregnant and breastfeeding women's acceptability of using intravaginal products and oral medications like the DPV VR and Truvada oral tablet. The MTN-041 study population will consist of HIV-uninfected women 18-40 years old who are currently or were recently (within two years) pregnant or breastfeeding, men aged 18 years or older whose partners are currently or were recently (within two years) pregnant or breastfeeding, grandmothers whose daughters or daughters-in-law are currently or were recently (within two years) pregnant or breastfeeding, and key informants (KIs), which include: health care professionals (HCPs), traditional birth attendants (TBAs), providers of family planning, antenatal, and traditional health services to women, providers of other social services to women, and community leaders. Up to 60 men and women will be selected at each site for participation in this study, for a maximum total of 240 study participants. This includes up to 50 FGD participants (currently or recently pregnant or breastfeeding women, male partners of women who are currently or were recently pregnant or breastfeeding, and grandmothers with currently or recently pregnant or breastfeeding daughters/daughters-in-law) and up to 10 KIs selected at each site, for a maximum total of 200 FGD participants and 40 KIs enrolled across all sites.


Recruitment information / eligibility

Status Completed
Enrollment 232
Est. completion date November 2, 2018
Est. primary completion date November 2, 2018
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Able and willing to provide written informed consent in one of the study languages. 2. Able and willing to complete the required study procedures. For currently or recently pregnant or breastfeeding women: 3. Between the ages of 18 to 40 years old (inclusive) at Enrolment, verified per site standard operating procedures (SOPs). 4. Currently or recently (within two years) pregnant or breastfeeding (by self-report). For male partners: 5. Aged 18 years or older at Enrolment, verified per site SOPs. 6. Identifies as a primary sexual partner of a woman who is currently or was recently (within two years) pregnant or breastfeeding. For grandmothers: 7. Aged 18 years or older at Enrolment, verified per site SOPs. 8. Identifies as the maternal or paternal grandmother of a daughter or daughter-in-law who is currently or was recently (within two years) pregnant or breastfeeding. Note: The term "daughter-in-law" includes women who are/were not married to their male partner during or after pregnancy. For service provider KIs: 9. Aged 18 years or older at Enrolment, verified per site SOPs. 10. Currently working as a clinician (e.g., obstetrician, nurse, pharmacist, etc.), traditional care provider (e.g., TBA, healer, midwife, etc.), social service provider (e.g., social worker, family planning counselor, etc.) or community health worker in one of the study countries, verified per site SOPs. 11. Experienced in providing services to pregnant and/or breastfeeding women. For community leader KIs: 12. Aged 18 years or older at Enrolment, verified per site SOPs. 13. Currently acting in a community leadership role (e.g., local chief, religious leader, etc.). Exclusion Criteria: 1. Has any condition that, in the opinion of the Investigator of Record (IoR)/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives. 2. For currently or recently pregnant or breastfeeding women: known HIV-positive status, verified per recent health record (e.g., health passport, ante-natal book, HIV test card, or similar document) or by self-report if health record(s) not available.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Focus Group Discussion (FGD)
No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on: Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding Perceptions of HIV risk during pregnancy and breastfeeding Perceived role of male partners during pregnancy and breastfeeding Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding Willingness to join a VR and/or oral PrEP study during pregnancy and breastfeeding
In-depth Interview (IDI)
No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics: Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding Perceptions of HIV risk during pregnancy and breastfeeding Perceived role of male partners during pregnancy and breastfeeding Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding How others in their professional and social networks and communities would view the VR and/or oral PrEP use by pregnant and breastfeeding women

Locations

Country Name City State
Malawi Blantyre Clinical Research Site Blantyre
South Africa Wits Reproductive Health and HIV Institute (WRHI) Clinical Research Site Johannesburg
Uganda Makerere University - Johns Hopkins University (MU-JHU) Research Collaboration Clinical Research Site Kampala
Zimbabwe Zengeza Clinical Research Site Harare

Sponsors (4)

Lead Sponsor Collaborator
Microbicide Trials Network Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)

Countries where clinical trial is conducted

Malawi,  South Africa,  Uganda,  Zimbabwe, 

References & Publications (2)

Flax VL, Hawley I, Ryan J, Chitukuta M, Mathebula F, Nakalega R, Seyama L, Taulo F, van der Straten A; MTN-041/MAMMA Study Team. After their wives have delivered, a lot of men like going out: Perceptions of HIV transmission risk and support for HIV preven — View Citation

van der Straten A, Ryan JH, Reddy K, Etima J, Taulo F, Mutero P, Taylor J, Piper J, Musara P; MTN-041/MAMMA Study Team. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study. J In — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptability of VR during pregnancy and breastfeeding, including willingness to use the VR or support its use Focus group discussions and key informant in-depth interviews 3-6 months during Q2/Q3 2018
Primary Acceptability of oral PrEP during pregnancy and breastfeeding, including willingness to use oral PrEP or support its use Focus group discussions and key informant in-depth interviews 3-6 months during Q2/Q3 2018
Secondary Product preferences during pregnancy and breastfeeding Focus group discussions and key informant in-depth interviews 3-6 months during Q2/Q3 2018
Secondary Sexual activity and contraceptive use during pregnancy and breastfeeding Focus group discussions and key informant in-depth interviews 3-6 months during Q2/Q3 2018
Secondary Perceptions of HIV risk during pregnancy and breastfeeding Focus group discussions and key informant in-depth interviews 3-6 months during Q2/Q3 2018
Secondary Community beliefs and practices related to pregnancy and breastfeeding, including use of oral medications and intravaginal products Focus group discussions and key informant in-depth interviews 3-6 months during Q2/Q3 2018
See also
  Status Clinical Trial Phase
Completed NCT03411577 - Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program N/A
Active, not recruiting NCT03112369 - Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use N/A
Not yet recruiting NCT03642314 - HIV Self-testing in Implementation PrEP Study N/A
Completed NCT01810315 - Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity Phase 1
Completed NCT00984971 - Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet Phase 1
Completed NCT00142935 - Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1 N/A
Active, not recruiting NCT03255915 - PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study) Early Phase 1
Completed NCT05037513 - Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky N/A
Recruiting NCT05087680 - An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South N/A
Recruiting NCT05804461 - Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico N/A
Completed NCT03148171 - Project WERK (Wellness Encouragement Respect Kinship) N/A
Completed NCT04791007 - OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults Early Phase 1
Recruiting NCT05412433 - Clinic-based HIV Identification and Prevention Project Using Electronic Resources N/A
Active, not recruiting NCT03977181 - The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms N/A
Recruiting NCT05165745 - Stick2PrEP Cisgender Women and Trans Individuals N/A
Completed NCT03719053 - Single Dose Truvada Study Phase 1
Recruiting NCT03856580 - Long-acting Biomedical HIV Prevention in Transgender Women N/A
Completed NCT02750540 - Optimization of a Tenofovir Enema for HIV Prevention Phase 1
Completed NCT01386294 - Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection Phase 3
Completed NCT00993811 - The Shang Ring: A Novel Male Circumcision Device for HIV Prevention Phase 1